Barcelona 23 March 2016. Sagrat Cor University Hospital and the Dr. Rosell Oncology Institute (IOR) have signed a strategic agreement to provide precision oncology and personalized cancer treatment. Under the terms of the agreement, IOR is to provide high quality care to private patients or those holding health insurance, as well as run Outpatient Services and clinical trials in the hospital.



This partnership with Sagrat Cor, led by Dr Rafael Rosell, a world leader in oncology, brings the experience of an internationally recognized team to the benefit of cancer patients. This union of two leaders in the fields of health service provision and oncology places the best of precision medicine and personalized cancer treatment at the disposal of patients.



With this agreement, Sagrat Cor will implement the IOR model of comprehensive cancer treatment with an innovative strategy: personalized therapy models based on genetic analyses. Each tumor has its own genetic fingerprint and its determination allows treatment to be tailored to each patient. The IOR team is comprised of medical oncologists specialized in different types of cancer.



A differential factor is that IOR has its own Molecular Oncology Laboratory which works closely with the oncologists to offer personalized treatments based on genetic characteristics of each patient’s tumor. As the team includes highly-skilled and specialized technical staff, biologists and pathologists, the quality, speed and accuracy of results is guaranteed.



Dr. Xavier Mate, Director of Sagrat Cor believes that this alliance "is important to our strategy of working with the best professionals in the field of oncology to improve cancer patient care. This initiative is something that benefits our patients, our partners and our team of professionals." Javier Rivela, CEO of IOR, feels the agreement is strategically important for them since it allows IOR to place all of its abilities in the fields of molecular diagnosis, clinical trials, and precision oncology at the disposal of patients.



Dr. Rafael Rosell, MD, PhD, is Medical Director and President of IOR, Chairman and Chief Scientific Officer of Pangaea Biotech, Director of the Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology (ICO) and founder of the Spanish Lung Cancer Group (SLCG). His many contributions to translational and medical oncology, with special emphasis on the field of non-small cell lung cancer with EGFR mutations, have earned him international recognition: in 2013 was recognized by the British journal The Lancet as the highest authority in the lung cancer in Europe, and he has received numerous awards in recognition of his tireless research into the causes and treatment of cancer.



About Sagrat Cor University Hospital

Sagrat Cor-Hospital Universitari has been part of the Xarxa Hospitalària d'Utilització Public (Catalan Public Health Network [XHUP]) since its inception in 1985. Founded between the 60s and 70s, Sagrat Cor covers all medical and surgical disciplines: thoracic surgery, cardiac surgery, neurosurgery, orthoplastic surgery and oncology, among others. Sagrat Cor has a strong background in care, teaching and investigation and is accredited as a teaching hospital by the Faculty of Medicine of the University of Barcelona as well as by the Ministry of Health for training of medical professionals. It also has agreements with other national and international universities for undergraduate and postgraduate training.